MedTrace Logo

Study to Evaluate the Efficacy of COVID19-0001-USR in Patients With Mild/or Moderate COVID-19 Infection in Outpatient

NCT04595136 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2021-05-26

No results posted yet for this study

Summary

Determine the efficacy and safety of COVID19-0001-USR in the treatment of SARS-COV-2 infection in mild to moderate manifestations administered via nebulization/inhalation.

Conditions

Interventions

DRUG

Drug COVID19-0001-USR

COVID19-0001-USR by nebulization for patients with mild and/or moderate SARS- COV-2

DRUG

normal saline

0.9% NS via nebulization

Sponsors & Collaborators

  • United Medical Specialties

    lead OTHER

Principal Investigators

  • Juan Jaller, MD · United Medical Specialties

  • Carlos A Riveros, MD · United Medical Specialties

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-02
Primary Completion
2021-07-30
Completion
2021-08-30

Countries

  • Colombia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04595136 on ClinicalTrials.gov